UC's $15 million to fight opioid deaths makes local headlines
A recap of media coverage following the HHS' HEALing Communities announcement
On Thursday, April 18, Health and Human Services (HHS) Secretary Alex Azar announced the launch of the HEALing Communities Study to help reverse our nation’s opioid crisis. Four states – Ohio, Kentucky, Massachusetts and New York, will receive over $350 million to support a multi-year study with the goal to cut opioid overdose deaths by 40% in three years. The announcement made news across Ohio and the region.
Funded by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), University of Cincinnati and Ohio State University will co-lead a $65.9 million effort across Ohio that will also partner with Recovery Ohio and Case Western Reserve University as well as additional universities and community organizations in 19 counties across Ohio. UC will be awarded $15.1 million over four years. Read the full story here.
HEALing Communities Award in the news:
WLW-700 AM(interview at 69:25 minute mark.)
Featured image at top: Jennifer Brown, PhD, presents at the UC / UC Health Opioid Symposium. Photo by Colleen Kelley/AHC Communication Services.
Related Stories
What parvovirus is and why it's on the rise
July 10, 2025
An infectious virus common in children is on the rise in the Tristate. The Cincinnati Health Department is warning of a rise in parvovirus in Hamilton County. The illness can present itself as a rash on the cheeks and is often called “slapped cheek” disease but can present more serious concerns in pregnant women. Kara Markham, MD, professor of obstetrics and gynecology at the University of Cincinnati College of Medicine recently appeared on Cincinnati Edition on WVXU to discuss how parvovirus is transmitted, the risk of serious cases and how to prevent it.
UC joins international Phase 1 trial testing CAR-T therapy for MS
July 10, 2025
The University of Cincinnati Gardner Neuroscience Institute is a trial site for a multicenter, international Phase 1 trial testing CAR-T cell therapy for patients with multiple sclerosis.
Inflammation, not symptoms, found to disrupt sleep in IBD...
July 9, 2025
Impaired sleep architecture in inflammatory bowel disease (IBD) is primarily driven by inflammatory activity rather than symptomatic flares as previously thought, according to a study published in Clinical Gastroenterology and Hepatology. Sleep architecture is the structural organization of a normal sleep cycle, encompassing the progression and distribution of different stages of sleep throughout a typical night’s rest.